Novel Coherence Imaging to Evaluate the Health of the Cervical Epithelium

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): Cervical cancer is a significant cause of morbidity in the U.S. with approximately 12,200 new cases and 4,200 deaths from this disease each year. As a screening tool, cervical cytology (the Papanicolaou smear) can reduce morbidity by detecting precancerous lesions; but it cannot locate dysplastic regions of the cervix, a necessity for biopsy guidance and therapy. Currently, regions suspected to be dysplastic are found by colposcopy with aceto-whitening, but this is a subjective diagnostic with limited accuracy and wide variability. The goal of this research project is to develop a novel coherence imaging platform for practical detection of cervical dysplasia. Reaching this goal will improve diagnosis and understanding of disease development. Many optical techniques have been proposed for detecting pre-cancerous lesions in the cervix, but none has yet been widely adopted, due primarily to limited performance. While high resolution methods show good sensitivity, the need to manually scan a probe across the ectocervix limits utility. In comparison, wide area imaging approaches examine more tissue area, but show limited specificity. Here we propose to create an imaging platform based on a multi-modality approach, combining wide field imaging, using multiplexed low coherence interferometry (mLCI) for comprehensive cervical mapping, with high resolution, depth-resolved nuclear morphology measurements, using angle-resolved LCI(a/LCI) for highly sensitive detection of dysplasia. The long term objective of this research is to create multi-modal instrument to enable diagnosis of cervical dysplasia. The following Specific Aims are proposed. 1) Develop multiplexed LCI for mapping the epithelial types of the cervix. The mLCI probe will conduct wide area scans of the ectocervix to map the squamous-to- columnar transition zone (T-zone). A proof of principle study at Duke will validate the mLCI probe, followed by a broader study at UCSF. Data will be compared to colpophotography, the current standard for assessing the T-zone. 2) Adapt angle-resolved LCI for detection of cervical dysplasia. a/LCI can detect dysplastic lesions via depth resolved nuclear morphology measurements. An initial in vivo pilot study will be conducted using an existing prototype and an optimized instrument will be developed to scan the ectocervix without needing to reposition the probe. The instrument will be used for proof of principle studies at Duke and then validated in a broader study at UCSF. To assess accuracy, a/LCI nuclear morphology measurements will be compared to histopathological evaluation of co-registered physical biopsies. 3) Integration of mLCI and a/LCI into a single imaging platform. The integrated platform will enable wide area mLCI scans, to map the T-zone of the cervix and serve as a guide for a/LCI nuclear morphology measurements to identify dysplasia at selected points. The instrument will be used in a pilot study at Duke and then applied in a clinical field test at UCSF. The optical imaging measurements will be compared to digital colpophotography to validate the T-zone mapping and to co-registered physical biopsies to confirm alignment of nuclear morphology with histopathological tissue state.